Amgen gains early US win for BiTE antibody Blincyto
This article was originally published in Scrip
Executive Summary
Well ahead of its 19 May 2015 Prescription Drug User Fee Act action date, Amgen’s bispecific T-cell engager (BiTE) antibody Blincyto (blinatumomab) won the FDA’s blessing on 3 December to enter the US market as a treatment for Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow, which has a median overall survival of just 3-5 months.
You may also be interested in...
J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.
Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.